Index removal puts Innospec in focus for benchmarked investors

Innospec (IOSP) has been removed from several Russell growth and small cap indexes, a shift that can affect benchmark-tracking funds and prompt investors to reassess how the stock fits into diversified portfolios.

For Innospec, the index removals come after a period where the 90 day share price return of 13.16% and year to date share price return of 8.32% point to building short term momentum, even as the 3 year total shareholder return declined 14.25%.

If this index reshuffle has you rethinking where growth might emerge next, it could be a useful moment to scan the market for 20 top founder-led companies

With Innospec trading at $82.63, alongside an indicated intrinsic discount of 25.44% and a 20.21% gap to analyst targets, investors now face a key question: is there genuine value on the table, or is the market already baking in future growth?

Most Popular Narrative: 16.8% Undervalued

At a last close of $82.63 versus a narrative fair value of $99.33, Innospec is framed as undervalued, with that gap hinging on specific growth and margin expectations.

The company's ongoing margin improvement initiatives, disciplined pricing strategies, and product mix optimization, particularly in Fuel Specialties and Performance Chemicals, are expected to boost gross margin and earnings as operational execution improves through the second half and into 2026. Innospec's strong cash position and lack of debt provide significant flexibility for organic investments and opportunistic M&A, aligning with the global trend of increased specialty chemicals demand for emerging wellness, personal care, and advanced materials markets, which could drive outsized revenue and net income growth over the long term.

Curious what sits behind that $99.33 figure for Innospec? The narrative leans on specific revenue growth, margin expansion and a future earnings multiple that might surprise you.

Result: Fair Value of $99.33 (UNDERVALUED)

However, the Innospec narrative still hinges on key uncertainties, including margin pressure from raw material cost swings and weaker Oilfield Services revenues if customer or regional risks persist.

Next Steps

With the mixed signals around Innospec's valuation and risks, it makes sense to look under the hood yourself and move quickly while sentiment is forming, starting with the 5 key rewards

Looking for more investment ideas beyond Innospec?

If you want to stress test what you have learned from Innospec, use the Simply Wall St Screener to surface fresh stock ideas before the crowd spots them.

• Zero in on potential mispricings by running a focused search through the 44 high quality undervalued stocks.
• Prioritize resilience by scanning companies that pass the filters in the 69 resilient stocks with low risk scores.
• Hunt for potential future standouts by checking the screener containing 19 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.